Details of the Drug Combinations

General Information of This Drug (ID: DMSH4DG)

Drug Name

Silibinin DMSH4DG

Synonyms

silibinin; Silybin; 22888-70-6; Flavobin; Silymarin I; Silybin A; Silybine; Silibinine; Silliver; Silibinin A; Silibininum; Silibinina; Flavobin Spofa; Silymarine I; Silibinin [INN]; Silymarine; Silibininum [INN-Latin]; Silibinine [INN-French]; Silibinina [INN-Spanish]; 7C3MT; UNII-33X338MNE4; EINECS 245-302-5; NSC 651520; Silimarin; Silibin; CHEBI:9144; 33X338MNE4; Silibinin (INN); NSC651520; C25H22O10; NCGC00091057-01; DSSTox_CID_6018; DSSTox_RID_77985; DSSTox_GSID_26018; (2R,3R)-3,5,7-trihydroxy-2-((2R,3R)-3-(4-hydroxy-

Indication

Disease Entry	ICD 11	Status	REF
Hepatic failure	DB99.7	Phase 2/3	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
I3C + Silibinin	DCF750H	I3C	Smoking	[2]
Docetaxel + Silibinin	DCVPMM8	Docetaxel	Upper GI Cancer	[3]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT03687073) Trial of Indole-3-Carbinol and Silibinin
3	ClinicalTrials.gov (NCT01829178) Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma